NF-κB activity can be enhanced by chromosomal translocations or mutations driving AML.
The expression of various components within the NF-κB pathway is increased in AML.
High proteasome activity might result in constitutive NF-κB activity in AML.
Novel compounds targeting the constitutive NF-κB activity are described.